Abstract

Merck & Co., Inc. will report its next quarterly results on August 4, 2026 Pre-Market; this preview compiles consensus expectations, company-anchored projections, last quarter’s baselines, and the key drivers likely to steer revenue, profit trajectory, and investor reaction this quarter.

Market Forecast

The market currently expects Merck & Co., Inc.’s quarterly revenue to be about 15.92 billion US dollars, roughly up 1.90% year over year, with adjusted EPS near 1.51 versus 2.22 a year earlier; by comparison, projection data based on the company’s prior report indicate revenue of 16.37 billion US dollars (+2.98% YoY), EBIT of 0.71 billion US dollars (-88.44% YoY), and EPS of approximately -0.27 (-113.60% YoY). Forecast margin details are not available, although last quarter’s gross margin ran at 76.21% and net margin at -26.03%, setting a high bar for any near-term profitability normalization. Pharmaceuticals remains the central revenue engine: it delivered 14.35 billion US dollars last quarter and underpinned the company’s 4.88% year-over-year top-line growth, with continued momentum expected from oncology label expansions and steady vaccine and specialty contributions. Within this, oncology-led therapies are considered the most promising near-term driver; these sit inside the 14.35 billion US dollars Pharmaceuticals contribution last quarter while the company-level revenue advanced 4.88% year over year.

Last Quarter Review

In the previous quarter, Merck & Co., Inc. reported revenue of 16.29 billion US dollars (+4.88% YoY), a gross profit margin of 76.21%, a GAAP net loss attributable to shareholders of 4.24 billion US dollars, a net profit margin of -26.03%, and adjusted EPS of -1.28, representing a year-over-year change of -157.66%. Quarter on quarter, net profit deteriorated sharply (quarter-on-quarter change of -243.10%), reflecting heavy expense timing and non-operational items that overwhelmed an otherwise solid gross margin base. Main business composition showed Pharmaceuticals at 14.35 billion US dollars, Animal Health at 1.79 billion US dollars, and Other at 146.00 million US dollars, together supporting the 4.88% year-over-year increase in total revenue and highlighting the concentration of growth in the core human therapeutics portfolio.

Current Quarter Outlook

Pharmaceuticals: cash generator with expanding oncology labels and early cardiometabolic entry

Management’s core revenue base remains concentrated in Pharmaceuticals, and this quarter’s setup reflects multiple product-level developments that can reinforce the top line despite a volatile EPS path. Oncology label expansions are expected to sustain demand: the company disclosed that its immuno-oncology therapy achieved the primary endpoint in a Phase 3 trial in mismatch repair–deficient endometrial cancer and also received expanded approval for muscle invasive bladder cancer in combination therapy; such updates typically support steady patient starts and duration trends in the near term. Although regulatory and commercialization timelines vary, these indications contribute to an increasingly diversified efficacy footprint across tumor types, which in turn can buffer seasonal fluctuations in other parts of the portfolio. Beyond oncology, the July approval of Lipfendra, a once-daily oral PCSK9 inhibitor for hypercholesterolemia, marks a strategic entry into a large cardiometabolic opportunity, but its revenue impact will be limited in the just-ended quarter and will begin to register in subsequent periods as launch logistics scale. The pace at which prescribers adopt an oral PCSK9 option will be a focal point for the back half of the year, with formulary coverage and real-world adherence shaping early run-rates. Taken together, this quarter’s Pharmaceuticals performance is likely to be defined by oncology consistency and incremental contribution from newly broadened labels, while the cardiometabolic launch builds gradually in the background, setting a multi-quarter revenue runway even as near-term EPS remains pressured by front-loaded investment and milestone accruals.

Oncology and immuno-oncology: the most promising growth vector this quarter

Oncology continues to anchor the “most promising” designation due to breadth of indications, ongoing label expansions, and supportive clinical readouts. The positive Phase 3 signal in endometrial cancer provides new optionality in a sizeable patient segment, strengthening the therapy’s role in gynecologic oncology and potentially improving regimen persistence where progression-free survival benefits are observed. In urologic oncology, the expanded combination approval in muscle invasive bladder cancer increases eligible use cases and complements earlier-stage and adjuvant settings, which tend to be monitored closely by payers and clinicians for real-world outcomes that can validate clinical-trial benefit over time. The revenue cadence this quarter will rely more on patient accrual dynamics than on pricing uplift, given a mature U.S. market and expanding ex-U.S. penetration that require time to translate into revenue. The net effect is a steady oncology contribution to overall Pharmaceuticals revenue, aided by new labels and deeper penetration in existing indications. Importantly, the oncology portfolio’s contribution to the consolidated gross margin should remain supportive, consistent with last quarter’s 76.21% gross margin baseline, even if the net margin remains under pressure due to R&D and commercialization investment cycles that likely persist through the quarter.

Profitability and expenses: near-term stock driver as investors weigh margins vs. pipeline spend

The sharp divergence between gross profitability and bottom-line metrics last quarter spotlighted the role of operating expenses, milestone accounting, and one-time items in driving EPS volatility. For the reported quarter, consensus anticipates modest revenue growth while company-derived projections suggest slightly stronger top-line momentum; both views imply that operating leverage will hinge on the scale and timing of R&D and SG&A outlays, especially in oncology, vaccines, and emerging franchises such as HIV prevention and cardiometabolic. With last quarter’s net margin at -26.03% and EPS at -1.28, the path to EPS normalization depends on reduced non-recurring charges and a slower growth rate in operating expenses versus sales, neither of which is guaranteed in a quarter where late-stage trials, new launch preparations, and life-cycle management activities are ramping. Investors will watch whether gross margin quality—supported by high-value therapeutics—translates into improved operating margin. While EBIT is projected at 0.71 billion US dollars for the current quarter, representing a year-over-year change of -88.44%, this appears more a function of expense timing and pipeline intensity than of product-level pricing or demand underperformance. As such, the most immediate valuation sensitivity likely resides in expense discipline commentary, clarity on any discrete items that may affect GAAP EPS, and management’s description of where the remainder of the year’s investment curve peaks relative to revenue growth.

HIV and prevention pipeline: optionality that can reshape medium-term mix

Merck & Co., Inc. is also progressing assets that, while not core to this quarter’s revenue, could prove consequential for the medium-term mix. The company outlined an early-access and licensing strategy for its investigational once-monthly oral HIV prevention candidate alimatravir, including royalty-free licenses with seven generic manufacturers to supply 129 low- and middle-income countries, alongside investments in manufacturing capacity and regional production support. This framework indicates a deliberate strategy to accelerate global accessibility if regulators approve the therapy, highlighting a prospective volume-driven, long-tailed contribution profile distinct from the company’s traditional oncology economics. Meanwhile, interest around the islatravir program and its combinations has increased following non-inferiority signals against standard-of-care regimens, with investors focusing on safety consistency and durability metrics that could define the commercial uptake curve. In the nearer term, these HIV initiatives translate into elevated R&D and pre-commercialization spend, which can weigh on sequential EPS even as they add pipeline depth. For this quarter’s print, the HIV franchise is more a narrative catalyst than a revenue driver, but updates on timelines, regulatory pathways, and partner execution can influence sentiment, particularly as investors evaluate the balance between near-term profitability and long-term growth.

Analyst Opinions

Bullish opinions outnumber neutral stances by a wide margin this season, with Buy-rated views comprising the clear majority over Hold ratings. Multiple large-cap healthcare teams maintain positive stances: Goldman Sachs reiterates a Buy with a 12-month price target around 137.00 US dollars, citing oncology durability and a de-risking profile for the broader pipeline; Wells Fargo’s research team keeps an Overweight view with a target near 145.00 US dollars, highlighting continued strength in the core immuno-oncology franchise and favorable label momentum; and Barclays lifts its target to 150.00 US dollars while maintaining an Overweight rating, reflecting anticipated upside from recent regulatory catalysts and execution across priority assets. Additional supportive calls include Buy stances from Scotiabank and Bank of America, which emphasize that oncology and late-stage assets can sustain above-peer revenue compounding even if reported EPS remains choppy as investment builds. Taken together, the majority view expects a constructive top-line trajectory this quarter with more variability below the line. Bulls point to two central arguments. First, revenue growth appears resilient against a backdrop of label expansions and new launches, as reflected by company-based projections of 16.37 billion US dollars (+2.98% YoY) and a still-elevated gross margin foundation that last quarter reached 76.21%. Second, while EPS may remain volatile—company-based projections imply EPS near -0.27 (YoY -113.60%) and EBIT of 0.71 billion US dollars (YoY -88.44%)—these figures are perceived as investment-phase mathematics rather than a deterioration in product economics or demand. In this framework, supportive clinical updates in endometrial and bladder cancer this quarter, alongside the emergent cardiometabolic and HIV opportunities, strengthen the case that near-term margin compression is a trade-off for multi-year revenue durability. Institutional commentary further underscores what will matter at the print and on the call. Bullish analysts expect oncology performance to validate revenue resilience and for management to frame expense trajectory in a way that outlines when operating leverage reappears. They will look for signals that expense intensity peaks as pivotal trials roll off and launch costs transition from build-out to maintenance. They also see optionality from the HIV prevention strategy and a differentiated cardiometabolic entry with Lipfendra, albeit acknowledging that the revenue contribution from these will skew to subsequent quarters. The dominant perspective is that incremental revenue stability and clear expense phasing can prompt re-rating potential even if GAAP earnings remains uneven near term.